Cholestyramine dosage and administration

Revision as of 15:51, 10 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Cholestyramine}} {{CMG}}; {{AE}} {{SS}} ==Dosage and Administration == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PREVALITE (CH...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Cholestyramine
PREVALITE® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Cholestyramine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

==Dosage and Administration

==

[1]


References

  1. ↑ "PREVALITE (CHOLESTYRAMINE) POWDER, FOR SUSPENSION [UPSHER-SMITH LABORATORIES INC.]". Retrieved 10 February 2014.

Template:Lipid modifying agents

Retrieved from "https://www.wikidoc.org/index.php?title=Cholestyramine_dosage_and_administration&oldid=941422"